Table 4.

Antitumor activity—response-evaluable population.

Dose CX-2029 (mg/kg)
0.10.250.512345All cohorts
Category(N = 3)(N = 2)(N = 6)(N = 3)(N = 7)(N = 10)(N = 4)(N = 2)(N = 37)
Confirmed partial response, n (%)2 (20.0)1 (50.0)3 (8.1)
 95% CI2.5–55.61.3–98.71.7–21.9
Stable disease, n (%)1 (33.3)4 (66.7)1 (33.3)3 (42.9)4 (40.0)13 (35.1)
 95% CI0.8–90.622.3–95.70.8–90.69.9–81.612.2–73.820.2–52.5
Progressive disease, n (%)2 (66.7)2 (100.0)2 (33.3)2 (66.7)3 (42.9)4 (40.0)4 (100.0)1 (50.0)20 (54.1)
 95% CI9.4–99.215.8–100.04.3–77.79.4–99.29.9–81.612.2–73.839.8–100.01.3–98.736.9–70.5
Not evaluable, n (%)1 (14.3)1 (2.7)
 95% CI0.4–57.90.1–14.2
Disease control,a n (%)3 (50.0)1 (33.3)2 (28.6)5 (50.0)1 (50.0)12 (32.4)
 95% CI11.8–88.20.8–90.63.7–71.018.7–81.31.3–98.718.0–49.8
  • Abbreviation: CI, confidence interval.

  • aDisease control was defined as a confirmed objective response by RECIST v1.1 or stable disease of at least 16-week (±7 days) duration.